Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors

Third Cell Therapy For Lymphoma Approved In The US

Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah. 

FDA - Food and Drug Administration approved text on document above stethoscope
Breyanzi was approved after an FDA delay related to manufacturing inspections • Source: Shutterstock

The US Food and Drug Administration approval of Bristol Myers Squibb Company’s chimeric antigen receptor T-cell (CAR-T) therapy Breyanzi (lisocabtagene maraleucel; liso-cel) has been a long time coming, but that has given the company time to prepare for launch against two established competitors.

The FDA cleared Breyanzi on 5 February to treat adult patients with certain types of large B-cell lymphoma who have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

S&E In Brief: Launch Updates And Political Headwinds

 

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By 

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.